Status:
COMPLETED
Phase II Study of Single Agent OSI-7904L in Patients With Gastric or Gastroesophageal (GEJ) Cancer
Lead Sponsor:
OSI Pharmaceuticals
Conditions:
Gastroesophageal Adenocarcinoma
Gastric Adenocarcinoma
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Multi-center, open-label, non-randomized Phase II study to evaluate the efficacy and safety of OSI-7904L in gastric and GEJ cancers. Those patients who do not derive clinical benefit after two cycles ...
Eligibility Criteria
Inclusion
- Documented locally advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction No prior chemotherapy for locally advanced or metastatic disease Adequate baseline bone marrow, hepatic and renal function Age \>= 18 years At least one target lesion
Exclusion
- Active or uncontrolled infections or other serious illnesses or other medical conditions (eg, hepatitis, HIV, chronic alcohol abuse) Symptomatic brain metastases which are not stable
Key Trial Info
Start Date :
October 1 2003
Trial Type :
INTERVENTIONAL
End Date :
October 1 2003
Estimated Enrollment :
43 Patients enrolled
Trial Details
Trial ID
NCT00073502
Start Date
October 1 2003
End Date
October 1 2003
Last Update
February 22 2006
Active Locations (11)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Pennsylvania Cancer Center
Philadelphia, Pennsylvania, United States, 19104
2
MD Anderson Cancer Center
Houston, Texas, United States, 77030
3
University of Utah, Huntsman Cancer Institute
Salt Lake City, Utah, United States, 84112
4
Dept Internal Medicine Gastrointestinal Oncology Unit
B-3000 Leuven, Belgium